Biomarkers associated with immunomodulation are being assessed with a renewed focus for dual treatment of lapatinib and trastuzumab (NCT02213042) or trastuzumab and pertuzumab (NCT03144947) in the neoadjuvant setting in advanced HER2+ breast cancer patients, which may further guide future combination strategies. Here, ERBB2 is linked to breast carcinoma.